AvalehtAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
Viimane sulgemishind
26,01 $
Tänane vahemik
25,75 $ - 26,39 $
Aasta vahemik
20,39 $ - 45,39 $
Turuväärtus
1,19 mld USD
Keskmine maht
436,45 tuh
P/E suhe
11,48
Dividendimäär
-
Põhibörs
NASDAQ
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | 191,84 mln | 0,33% |
Põhitegevusega seonduv kulu | 73,33 mln | 63,34% |
Puhastulu | 17,35 mln | −57,09% |
Puhaskasumimarginaal | 9,04 | −57,24% |
Puhaskasum aktsia kohta | 0,93 | −3,12% |
EBITDA | 39,45 mln | −44,00% |
Tõhus maksumäär | 19,35% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 276,21 mln | 10,27% |
Kogu vara | 1,67 mld | 7,83% |
Kõik kohustused | 889,48 mln | 8,80% |
Kogu omakapital | 776,75 mln | — |
Emiteeritud aktsiate arv | 45,95 mln | — |
Hinna ja väärtuse suhe P/B | 1,55 | — |
Varade tasuvus | 3,86% | — |
Kapitali tasuvus | 4,45% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 17,35 mln | −57,09% |
Põhitegevuse rahakäive | 52,58 mln | −12,31% |
Investeeringute raha | −19,62 mln | 43,27% |
Finantseerimise raha | −4,35 mln | 80,95% |
Raha ja raha ekvivalentide muutus | 28,58 mln | 1 044,41% |
Tasuta rahavoog | 44,19 mln | 76,36% |
Teave
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Asutatud
1996
Veebisait
Töötajate arv
2 028
